Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075894 · ClinicalTrials.gov registry record · Phase 1
Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00075894: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00075894 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00075894, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as alanosine, use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of alanosine in treating patients with high-grade progressive or recurrent malignant gliomas.
Interventions
- DRUG L-alanosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2004-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00075894
The ClinicalTrials.gov registry entry for NCT00075894 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which L-alanosine is the first listed.
NCT00075894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00075894 about?
NCT00075894 is a clinical study titled "Alanosine in Treating Patients With Progressive or Recurrent Malignant Gliomas". RATIONALE: Drugs used in chemotherapy, such as alanosine, use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of alanosine in treating patients with high-grade progressive or recurrent malignant gli...
What is the current status of trial NCT00075894?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2004-03.
What interventions are being tested in trial NCT00075894?
The interventions under investigation include: L-alanosine (DRUG).
Who is sponsoring clinical trial NCT00075894?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.